Citation Report
List of articles citing

The influence of age and sex on the clearance of cytochrome P450 3A substrates

DOI: 10.2165/00003088-200544010-00002
Clinical Pharmacokinetics, 2005, 44, 33-60.

Source: https://exaly.com/paper-pdf/39421259/citation-report.pdf
Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
227	Effect of age on in vitro triazolam biotransformation in male human liver microsomes. **2004**, 308, 874-9		25
226	The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. **2004**, 309, 730-6		30
225	Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. **2004** , 309, 720-9		48
224	Host determinants of antiretroviral drug activity. **2005**, 18, 543-9		13
223	Effects of age and sex on olanzapine plasma concentrations. **2005**, 25, 570-4		47
222	Age-related changes in liver structure and function: Implications for disease ?. **2005**, 40, 650-9		306
221	Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. **2005**, 182, 414-9		6
220	Invloed van leeftijd en geslacht op de werking van Cytochroom P450 CYP3A. **2005**, 43, 220-220		
219	Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. **2005**, 26, 1585-95		171
218	Modulation of cytochrome P450 activity: implications for cancer therapy. **2005**, 6, 780-9		94
217	Growth and hepatic in vitro metabolism of ergotamine in mice divergently selected for response to endophyte toxicity. **2005**, 35, 531-48		15
216	Clinical pharmacokinetics: brief reports. **2005**, 21, 25-26		
215	Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. **2005**, 22, 541-57		44
214	Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. **2006**, 2, 273-83		39
213	Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. **2006**, 29, 735-68		64
212	The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships. *Clinical Pharmacokinetics*, **2006**, 45, 433-48	6.2	21
211	Clinical pharmacokinetics of ranolazine. *Clinical Pharmacokinetics*, **2006**, 45, 469-91	6.2	110

210	Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults. **2006**, 46, 345-52		10
209	CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. **2006**, 16, 637-45		68
208	The effect of chronic lorazepam administration in aging mice. **2006**, 1118, 13-24		5
207	Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. **2006**, 50, 3548-55		50
206	The clinical implications of antiretroviral pharmacogenomics. **2006**, 7, 587-96		16
205	Developmental changes of aldehyde oxidase in postnatal rat liver. **2007**, 22, 119-24		10
204	Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results. *Therapeutic Drug Monitoring*, **2007**, 29, 248-60	3.2	52
203	Preliminary experience with the use of oral linezolid in infants for the completion of antibiotic therapy in the outpatient setting after admission to the pediatric intensive care unit. **2006**, 13, 473-7		144
202	Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. **2007**, 47, 485-96		53
201	The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. **2007**, 19, 253-64		107
200	Pharmacological Differences between Men and Women. **2007**, 325-338		1
199	The current state of knowledge on age, sex, and their interactions on clinical pharmacology. **2007**, 82, 87-96		194
198	Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. **2007**, 82, 410-26		77
197	Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. **2007**, 63, 24-35		46
196	Clinical pharmacology in the geriatric patient. **2007**, 21, 217-30		199
195	Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. **2008**, 392, 1093-108		430
194	Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. **2008**, 64, 17-24		34
193	Effects of Sairei-to on the pharmacokinetics of nifedipine in rats. **2008**, 22, 12-7		3

192	Biological rhythms: a neglected factor of variability in pharmacokinetic studies. **2008**, 97, 1099-108	19
191	Vitamin E in human health and disease. **2008**, 45, 417-50	116
190	Sex-specific differences in CYP450 isoforms in humans. **2008**, 4, 413-24	121
189	A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. **2008**, 49, 347-61	37
188	Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. **2008**, 26, 2350-7	186
187	Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies. **2008**, 5, 316-23	6
186	Pharmacologic consideration for the use of antiretroviral agents in the elderly. **2008**, 48, 1212-25	22
185	Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. **2008**, 48, 1350-5	68
184	Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. **2008**, 49, 358-68	29
183	The clinical significance of gastrointestinal changes with aging. **2008**, 11, 651-60	107
182	Not Geropharmacotherapy 101. **2007**, 2, 715-8	1
181	Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes. **2009**, 37, 90-6	33
180	Sex differences in the expression of hepatic drug metabolizing enzymes. **2009**, 76, 215-28	497
179	Pharmacogenomics of CYP3A: considerations for HIV treatment. **2009**, 10, 1323-39	36
178	Tissue distribution of CYP3A29 mRNA expression in Bama miniature pig by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). **2009**, 39, 423-9	21
177	Outcome of acute liver failure in the elderly. **2009**, 15, 1481-7	27
176	Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. **2009**, 85, 198-203	80
175	Aging and Medications: Past, Present, Future. **2009**, 85, 3-10	10

174	Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. **2009**, 86, 497-502		15
173	Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. **2009**, 26, 715-37		58
172	Drug Metabolism. **2009**, 131-173		13
171	Sex Differences of Drug-metabolizing Enzyme: Female Predominant Expression of Human and Mouse Cytochrome P450 3A Isoforms. **2009**, 55, 325-337		28
170	Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans. *Therapeutic Drug Monitoring*, **2010**, 32, 346-52	3.2	17
169	Mechanisms and Consequences of Drug-Drug Interactions. **2010**, 1		
168	Response to Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as differentiating factor. **2010**, 66, 957-958		4
167	A highly sensitive SPE- liquid/liquid extraction -RPLC analytical method for the determination of 6-hydroxycortisol and cortisol in cancer patients' urine. **2010**, 25, 75-83		3
166	Diagnosis and treatment of heart disease: are women different from men?. **2010**, 53, 227-36		66
165	State of the art in therapeutic drug monitoring. **2010**, 48, 437-46		11
164	Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. **2010**, 26, 635-43		27
163	Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. **2010**, 11, 1389-402		34
162	Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. *Clinical Pharmacokinetics*, **2010**, 49, 589-606	6.2	26
161	Risk factors for idiosyncratic drug-induced liver injury. **2010**, 138, 2246-59		233
160	Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. **2011**, 27, 1585-93		13
159	Is antiarrhythmic treatment in the elderly different? a review of the specific changes. **2011**, 28, 617-33		22
158	Acute abdominal pain in the older adult. **2011**, 29, 429-48, x		39
157	Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. **2011** , 153, 141-7		9

156	Quantitative shot-gun proteomics and MS-based activity assay for revealing gender differences in enzyme contents for rat liver microsome. **2011**, 74, 2734-44	22
155	Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. **2011**, 31, 302-8	28
154	Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. **2011**, 163, 53-67	161
153	Drug-induced autoimmune-like hepatitis. **2011**, 56, 958-76	178
152	Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. **2011**, 67, 493-506	45
151	Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. **2011**, 6, 181-6	7
150	Hepatocyte nuclear factor 4 regulates expression of the mouse female-specific Cyp3a41 gene in the liver. **2011**, 39, 490-7	6
149	Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. **2011**, 11, 130-7	45
148	Vital Functions. **2012**, 239-262	
147	Sedation and analgesia usage in severe pandemic H1N1 (2009) infection: a comparison to respiratory failure secondary to other infectious pneumonias. **2012**, 46, 9-20	10
146	Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. **2012**, 8, 1609-18	15
145	Age-Dependent Expression of Human Drug-Metabolizing Enzymes. **2012**, 1	3
144	Developmental changes of aldehyde oxidase activity and protein expression in human liver cytosol. **2012**, 27, 543-7	16
143	Sex Differences in Drug Metabolism. **2012**, 1	1
142	Introduction to Drug Metabolism. **2012**, 285-300	3
141	Women and the management of acute coronary syndrome. **2012**, 90, 1151-9	13
140	Pharmacokinetics and Pharmacodynamics: The Role of Sex and Gender. **2012**, 183-194	3
139	Pharmacological Differences between Men and Women. **2012**, 383-394	2

138	Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. **2012**, 32, 87-97	38
137	Zolpidem for insomnia. **2012**, 13, 879-93	154
136	Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. **2012**, 68, 1175-82	24
135	Species-specific toxicity of troglitazone on rats and human by gel entrapped hepatocytes. **2012**, 258, 19-25	13
134	Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. **2013**, 84, 329-35	5
133	Effect of age on hepatic cytochrome P450 of Ross 708 broiler chickens. **2013**, 92, 1283-92	13
132	Predicted metabolic drug clearance with increasing adult age. **2013**, 75, 1019-28	38
131	Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability. **2013**, 102, 541-55	16
130	Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. **2013**, 35, 604-11	33
129	From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. **2013**, 452, 14-35	48
128	Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. **2013**, 138, 103-41	2110
127	Clinical pharmacokinetics of antiretroviral drugs in older persons. **2013**, 9, 573-88	27
126	Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. **2013**, 40, 157-76	32
125	Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy. **2013**, 53, 276-84	10
124	Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects. **2013**, 33, 363-70	18
123	Intraindividual and interindividual variabilities in endogenous cortisol 6‐hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. **2013**, 41, 475-9	11
122	Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. **2014**, 29, 120-8	23
121	Precursors for cytochrome P450 profiling breath tests from an in silico screening approach. **2014**, 8, 046001	1

120	Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. **2014**, 54, 282-90	62
119	Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects. **2014**, 31, 731-6	10
118	Zopiclone's residual effects on actual driving performance in a standardized test: a pooled analysis of age and sex effects in 4 placebo-controlled studies. **2014**, 36, 141-50	22
117	Importance of hematocrit for a tacrolimus target concentration strategy. **2014**, 70, 65-77	72
116	Effect of hepatic function on the EC50 of midazolam and the BIS50 at the time of loss of consciousness. **2014**, 15, 743-9	4
115	Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. **2014**, 144, 134-61	66
114	Single-dose pharmacokinetics of the renin inhibitor ACT-077825 in elderly and young subjects of both sexes. **2014**, 94, 135-42	1
113	CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. **2015**, 80, 276-84	39
112	Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B. **2015**, 21, 8373-81	11
111	Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. **2015**, 47, 470-519	46
110	Alterations in drug disposition in older adults. **2015**, 11, 491-508	64
109	Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients. **2015**, 29, 224-30	17
108	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. **2015**, 36, 3238-49	129
107	Drug-induced liver injury: Interactions between drug properties and host factors. **2015**, 63, 503-14	231
106	EPMA position paper in cancer: current overview and future perspectives. **2015**, 6, 9	60
105	Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy. **2015**, 32, 999-1008	54
104	Sex-dependent regulation of hepatic CYP3A by growth hormone: Roles of HNF6, C/EBP and RXR **2015**, 93, 92-103	25
103	Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method. **2016**, 119, 284-90	31

102	Advances in Computational Prediction of Regioselective and Isoform-Specific Drug Metabolism Catalyzed by CYP450s.. **2016**, 1, 6571-6597	11
101	Farmacologí de las benzodiazepinas utilizadas en anestesia-reanimaci. **2016**, 42, 1-11	1
100	Farmacologia delle benzodiazepine utilizzate in anestesia-rianimazione. **2016**, 21, 1-11	
99	Urinary 6-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach. **2016**, 18, 1254-1261	24
98	Clinical characteristics of drug-induced liver injury and related risk factors. **2016**, 12, 2606-2616	31
97	Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. **2016**, 43, 481-504	56
96	Autoimmune-like drug-induced liver injury: a review and update for the clinician. **2016**, 12, 1291-1301	14
95	Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses. **2016**, 355, i5826	33
94	Pharmacokinetics and Pharmacodynamics for Medical Students: A Proposed Course Outline. **2016**, 56, 1180-95	7
93	Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. **2016**, 48, 88-112	82
92	Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes. **2016**, 33, 233-48	5
91	ESR1 polymorphisms and statin therapy: a sex-specific approach. **2016**, 16, 507-513	9
90	Monocrotophos Induces the Expression of Xenobiotic Metabolizing Cytochrome P450s (CYP2C8 and CYP3A4) and Neurotoxicity in Human Brain Cells. **2017**, 54, 3633-3651	15
89	2017, Sexual Dimorphism, Sexual Pluralism, and More. **2017**, 39, 1-5	2
88	Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. **2017**, 49, 197-211	210
87	Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. **2017**, 102, 989-996	7
86	DOLOR ABDOMINAL AGUDO EN EL ADULTO MAYOR. **2017**, 28, 282-290	
85	Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3. **2017**, 55, 268-277	12

84	Gender-based personalized pharmacotherapy: a systematic review. **2017**, 295, 1305-1317		26
83	Gender differences in the effects of cardiovascular drugs. **2017**, 3, 163-182		126
82	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. **2017**, 44, 1083-1088		13
81	Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn's Disease. **2017**, 23, 75-81		10
80	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. *Frontiers in Pharmacology*, **2017**, 8, 358	5.6	29
79	mRNA expression of drug metabolism enzymes and transporter genes at birth using human umbilical cord blood. **2018**, 32, 422-435		3
78	Drug-Induced Liver Injury: Perspectives from Pathology. **2018**, 4, 182-192		4
77	The role of hepatic cytochrome P450s in the cytotoxicity of dronedarone. **2018**, 92, 1969-1981		6
76	Synthesis and molecular docking of new roflumilast analogues as preferential-selective potent PDE-4B inhibitors with improved pharmacokinetic profile. **2018**, 148, 477-486		7
75	Abdominal Pain in Older Patients. **2018**, 217-234		
74	Pharmacokinetics and drug metabolism of antibiotics in the elderly. **2018**, 14, 1087-1100		15
73	Challenges and innovations of drug delivery in older age. **2018**, 135, 3-38		23
72	Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management. **2018**, 35, 589-602		7
71	A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum. **2019**, 20,		6
70	Inter-ethnic differences in CYP3A4 metabolism: A Bayesian meta-analysis for the refinement of uncertainty factors in chemical risk assessment. **2019**, 12, 100092		9
69	Fatty acids modulate the expression of pyruvate kinase and arachidonate-lipoxygenase through PPARγ/CYP2C45 pathway: a link to goose fatty liver. **2019**, 98, 4346-4358		4
68	Integrating physiologically based kinetic (PBK) and Monte Carlo modelling to predict inter-individual and inter-ethnic variation in bioactivation and liver toxicity of lasiocarpine. **2019**, 93, 2943-2960		5
67	Sex-Gender Variable: Methodological Recommendations for Increasing Scientific Value of Clinical Studies. **2019**, 8,		35

66	Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease. **2019**, 11,		7
65	Pharmacotherapy options and drug development in managing periprosthetic joint infections in the elderly. **2019**, 20, 1109-1121		1
64	Urinary phthalate metabolite and bisphenol A levels in the Korean adult population in association with sociodemographic and behavioral characteristics: Korean National Environmental Health Survey (KoNEHS) 2012-2014. **2019**, 222, 903-910		10
63	Zolpidem and Gender: Are Women Really At Risk?. **2019**, 39, 189-199		22
62	Roflumilast analogs with improved metabolic stability, plasma protein binding, and pharmacokinetic profile. **2019**, 11, 886-897		4
61	Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. **2020**, 34, 326-335		12
60	Investigations on hepatic and intestinal drug-metabolizing cytochrome P450 enzymes in wild boar compared to domestic swine. **2020**, 66, 1		3
59	Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. **2019**, 37, 15		1
58	Safety and efficacy of antiarrhythmic drugs. **2020**, 789-798		
57	Pharmacokinetic considerations about antiseizure medications in the elderly. **2020**, 16, 983-995		2
56	Orally Administered Koumine Persists Longer in the Plasma of Aged Rats Than That of Adult Rats as Assessed by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry. *Frontiers in Pharmacology*, **2020**, 11, 1113	5.6	3
55	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. **2020**, 40, 287-292		12
54	Sex differences in pharmacokinetics predict adverse drug reactions in women. **2020**, 11, 32		78
53	Influence of Polymorphisms on -Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation. **2020**, 21,		3
52	The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. **2020**, 86, 2051-2062		8
51	Cytochrome P450 expression, induction and activity in human induced pluripotent stem cell-derived intestinal organoids and comparison with primary human intestinal epithelial cells and Caco-2 cells. **2021**, 95, 907-922		6
50	Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study. **2021**, 12, 668-671		0
49	Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly. **2021**, 61, 193-203		1

48	Cardiovascular Medications. **2021**, 597-642		1
47	Drug-Induced Liver Injury in Older Adults. **2021**, 1391-1406		
46	Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method. *Frontiers in Pharmacology*, **2020**, 11, 600255	5.6	3
45	Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. *Cardiovascular Therapy and Prevention (Russian Federation)*, **2021**, 20, 2847	0.9	1
44	Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end-stage renal disease. **2021**, 14, 2034-2042		2
43	Sex-related differences in the pharmacological treatment of heart failure. **2021**, 229, 107891		4
42	Long-term exposure to polypharmacy impairs cognitive functions in young adult female mice. **2021**, 13, 14729-14744		2
41	Commentary on "Sex and Gender Differences in Clinical Pharmacology: Implications for Transgender Medicine". **2021**, 110, 863-865		0
40	Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects. **2021**, 10, 1469-1477		0
39	Sex-Biased Expression of Pharmacogenes across Human Tissues. **2021**, 11,		3
38	Immunosuppression-related neurological disorders in kidney transplantation. **2021**, 34, 539-555		8
37	Geschlechtsspezifische Unterschiede in der Pharmakotherapie. **2008**, 31-47		1
36	Drug-Induced Liver Injury in Older Adults. **2020**, 1-16		1
35	Diazepam in the Elderly: Looking Back, Ahead, and at the Evidence. **2020**, 40, 215-219		4
34	Are TKIs favourable for the elderly with non-small-cell lung cancer?. **2016**, 7, 46871-46877		6
33	Progress in the Consideration of Possible Sex Differences in Drug Interaction Studies. **2019**, 20, 114-123		4
32	Itraconazole Bioequivalence Revisited: Influence of Gender on Highly Variable Drugs. **2007**, 1, 7-13		5
31	Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. **2015**, 4, 198-208		17

30	Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort. **2014**, 103, 33-40		13
29	Tacrolimus Dose-Conversion Ratios Based on Switching of Formulations for Patients with Solid Organ Transplants. **2021**, 74, 317-326		
28	CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation. **2022**, 809, 146007		1
27	PHARMACOLOGY ACROSS THE AGING CONTINUUM. **2009**, 257-264		
26	SEX DIFFERENCES IN PHARMACOLOGY. **2009**, 251-256		
25	Special situations, market fragmentation II: sex differences. **2010**, 387-402		
24	Drug-Induced Liver Injury. **2012**, 409-420		1
23	Essential arterial hypertension in women, or female arterial hypertension?. *Cardiovascular Therapy and Prevention (Russian Federation)*, **2012**, 11, 79-84	0.9	3
22	Errores en el diagnóstico de apendicitis aguda en ancianos. Estudio de un caso clínico y revisión de la literatura. *Cirujano General*, **2016**, 38, 149-157	0.1	
21	Special Situations, Market Fragmentation II: Sex Differences. **2016**, 361-375		
20	Genderspecific features of antioxidant protection and efficacy of atorvastatin in patients with stable forms of coronary heart disease. *Klinicheskaia Meditsina*, **2017**, 95, 398-403	0.2	1
19	Sex-specific pharmacological differences. **2022**, 405-424		
18	Medikamentös-toxischer Leberschaden (DILI). *Pathologie*, **2020**, 117-157	0	
17	Therapeutic Drug Monitoring of Antibiotics in the Elderly: A Narrative Review. *Therapeutic Drug Monitoring*, **2021**, 44,	3.2	2
16	Research Progress on the Correlation between Polypharmacy and Falling in the Elderly. *Advances in Clinical Medicine*, **2021**, 11, 5578-5586	0	
15	Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions.. *Lancet Neurology, The*, **2022**,	24.1	7
14	The liver and gallbladder in the geriatric population. **2022**, 247-253		
13	Potential drug-drug interaction between tolvaptan and warfarin in a geriatric patient with heart failure.. *Clinical Case Reports (discontinued)*, **2022**, 10, e05592	0.7	1

12	DataSheet_1.pdf. **2020**,		
11	THE EFFECT OF GENDER FACTORS ON CERTAIN ASPECTS OF THE TREATMENT FOR VASCULAR DISEASES (literature review). *Problemy Zdorov?? ?kologii*, **2015**, 13-19	0.2	
10	Harnessing Clinical Trial and Real-World Data Towards an Understanding of Sex Effects on Drug Pharmacokinetics, Pharmacodynamics and Efficacy. *Frontiers in Pharmacology*, 13,	5.6	0
9	Safety of antithrombotic therapy in elderly patients: analysis of the Russian Pharmacovigilance Database. *Hirurg*, **2022**, 51-59	0.1	
8	Aging in gastrointestinal system. **2023**, 339-345		0
7	Fate of drug-metabolizing enzymes in cardiovascular diseases: Concepts and challenges. **2022**, 231-258		0
6	Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.		2
5	The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.		0
4	A Randomized, Open-Label, Phase I Clinical Study of Dalpiciclib With Different Specifications After Process Modification in Healthy Chinese Volunteers.		0
3	Sex and Age Influence on Association of CYP450 Polymorphism with Midazolam Levels in Critically Ill Children. **2022**, 12, 2797		0
2	Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants.		0
1	Drug-induced liver injury: a comprehensive review. **2023**, 16, 175628482311634		0